Progress in cardiovascular diseases最新文献

{"title":"Introduction to assorted topics 2024","authors":"Carl J. Lavie","doi":"10.1016/j.pcad.2024.07.004","DOIUrl":"10.1016/j.pcad.2024.07.004","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"85 ","pages":"Page 1"},"PeriodicalIF":5.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The weekly mortality for ischemic heart disease in the US still peaks on mondays","authors":"","doi":"10.1016/j.pcad.2024.01.007","DOIUrl":"10.1016/j.pcad.2024.01.007","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"85 ","pages":"Pages 118-119"},"PeriodicalIF":5.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139467407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Normative values for body composition in 22,191 healthy Norwegian adults 20–99 years: The HUNT4 study","authors":"","doi":"10.1016/j.pcad.2024.06.002","DOIUrl":"10.1016/j.pcad.2024.06.002","url":null,"abstract":"<div><h3>Background</h3><p>Body mass, body mass index (BMI), and body composition components are essential for health and longevity. Considering the influence of demographic factors on body composition, there is a need for tailored reference values based on age-, sex-, and geography. We aimed to construct a comprehensive reference material on body composition in healthy Norwegian adults.</p></div><div><h3>Methods</h3><p>In this cross-sectional study, we estimated age- and sex-specific reference values for body-, fat-, and muscle mass variables using multi-frequency bioelectrial impedance analysis (such as body fat percentage, skeletal muscle mass and visceral fat area) in 22,191 healthy adults aged 20–99 years participating in the Trøndelag Health Study 4 (HUNT4). We calculated the fat mass and skeletal muscle mass index as the total fat and muscle mass relative to height squared and used general linear models to explore the associations between physical activity (PA), BMI, and age.</p></div><div><h3>Results</h3><p>With a BMI (kg/m²) of 25.4 (SD 5.1) and 26.0 (4.5) for women and men, respectively, the youngest age group (20–39 yrs) had a lower BMI compared to their counterparts aged 40–59 years (26.3 [4.5] and 27.5 [3.8]) and ≥ 60 years (25.7 [4.1] and 26.5 [3.4]), respectively. Those aged 20–39 years also had the lowest values for the different body fat variables measured. Fat mass index (kg/m²) was 8.41 (4.00) and 5.81 (3.29) for women and men aged 20–39 years, respectively, compared to 9.25 (3.21) and 6.86 (2.46) for those aged ≥60 years. The oldest age group had the lowest values for the various muscle mass variables; women and men aged 60+ years had a skeletal muscle mass index (kg/m²) of 8.91 (0.85) and 10.96 (1.00), respectively. Corresponding values for those aged 20–39 years were 9.33 (0.97) and 11.49 (1.15). For all age groups and both sexes, regular physical activity was associated with lower levels of fat mass, whereas the association between muscle mass and PAwas less conclusive. When using body fat percentage as an obesity measure, we observed a much higher obesity prevalence (41.2%) in the study population compared to BMI (17.3%).</p></div><div><h3>Conclusions</h3><p>Our study offers a comprehensive reference for body composition among healthy adults in Norway, aiding the identification of abnormal fat and muscle mass values across age groups. We also highlight that BMI often misclassifies individuals with adiposity levels in the overweight or obese category as lean. Therefore, incorporating body composition when defining obesity could enable early intervention to prevent cardiometabolic diseases.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"85 ","pages":"Pages 82-92"},"PeriodicalIF":5.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estrogen and cardiovascular disease","authors":"Felice Gersh ,&nbsp;James H. O'Keefe ,&nbsp;Andrew Elagizi ,&nbsp;Carl J. Lavie ,&nbsp;Jari A. Laukkanen","doi":"10.1016/j.pcad.2024.01.015","DOIUrl":"10.1016/j.pcad.2024.01.015","url":null,"abstract":"<div><p>A large body of scientific research accumulated over the past twenty years documents the cardiovascular (CV) benefits of estradiol (E2) and progesterone (P4) in reproductive aged women. In contrast, accelerated development of CV disease (CVD) occurs in the absence of ovarian produced E2 and P4. Hormone replacement therapy (HRT) with E2 and P4 has been shown to cause no harm to younger menopausal women. This robust scientific data supports a reconsideration of the prescriptive use of E2 and P4 as preventative therapeutics for the reduction of CVD, even without additional large-scale studies of the magnitude of the Women's Health Initiative (WHI). With the current expanded understanding of the critical modulatory role played by E2 on a multitude of systems and enzymes impacting CVD onset, initiation of HRT shortly after cessation of ovarian function, known as the “Timing Hypothesis”, should be considered to delay CVD in recently postmenopausal women.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"84 ","pages":"Pages 60-67"},"PeriodicalIF":9.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in preventive cardiology","authors":"Adham El Sherbini ,&nbsp;Robert S. Rosenson ,&nbsp;Mahmoud Al Rifai ,&nbsp;Hafeez Ul Hassan Virk ,&nbsp;Zhen Wang ,&nbsp;Salim Virani ,&nbsp;Benjamin S. Glicksberg ,&nbsp;Carl J. Lavie ,&nbsp;Chayakrit Krittanawong","doi":"10.1016/j.pcad.2024.03.002","DOIUrl":"10.1016/j.pcad.2024.03.002","url":null,"abstract":"<div><p>Artificial intelligence (AI) is a field of study that strives to replicate aspects of human intelligence into machines. Preventive cardiology, a subspeciality of cardiovascular (CV) medicine, aims to target and mitigate known risk factors for CV disease (CVD). AI's integration into preventive cardiology may introduce novel treatment interventions and AI-centered clinician assistive tools to reduce the risk of CVD. AI's role in nutrition, weight loss, physical activity, sleep hygiene, blood pressure, dyslipidemia, smoking, alcohol, recreational drugs, and mental health has been investigated. AI has immense potential to be used for the screening, detection, and monitoring of the mentioned risk factors. However, the current literature must be supplemented with future clinical trials to evaluate the capabilities of AI interventions for preventive cardiology. This review discusses present examples, potentials, and limitations of AI's role for the primary and secondary prevention of CVD.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"84 ","pages":"Pages 76-89"},"PeriodicalIF":9.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140069040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omega-3 fatty acids in primary and secondary prevention of cardiovascular diseases","authors":"Austin Tutor ,&nbsp;Evan L. O'Keefe ,&nbsp;Carl J. Lavie ,&nbsp;Andrew Elagizi ,&nbsp;Richard Milani ,&nbsp;James O'Keefe","doi":"10.1016/j.pcad.2024.03.009","DOIUrl":"10.1016/j.pcad.2024.03.009","url":null,"abstract":"<div><p>Even with substantial progress in primary and secondary prevention, cardiovascular disease (CVD) persists as a major cause of mortality and morbidity globally. Omega-3 polyunsaturated fatty acids (Ω-3 PUFAs) have gained considerable attention for their ability to improve CV health and prognosis. Metanalyses of randomized controlled trials have demonstrated Ω-3 PUFAs' positive impact on CVD outcomes for both primary and secondary prevention endpoints. Marine Ω-3 PUFAs also improve CVD risk factors including blood pressure, lipids, and inflammation; however, many physicians do not recommend Ω-3 PUFAs, largely due to inconsistent results in randomized trials. In this comprehensive review article, we evaluate both historic and current data concerning primary and secondary prevention of CVD with use of Ω-3 PUFAs, delve into the potential causes for the varied results, and examine the most current recommendations on the usage of Ω-3 PUFAs.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"84 ","pages":"Pages 19-26"},"PeriodicalIF":9.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men","authors":"Srikanth Krishnan ,&nbsp;Jairo Aldana-Bitar ,&nbsp;Ilana Golub ,&nbsp;Keishi Ichikawa ,&nbsp;Ayesha Shabir ,&nbsp;Marziyeh Bagheri ,&nbsp;Hossein Hamidi ,&nbsp;Travis Benzing ,&nbsp;Sina Kianoush ,&nbsp;Matthew J. Budoff","doi":"10.1016/j.pcad.2024.02.015","DOIUrl":"10.1016/j.pcad.2024.02.015","url":null,"abstract":"<div><p>The debate over the cardiovascular (CV) implications of testosterone therapy (TT) have resulted in diverging safety recommendations and clinical guidelines worldwide. This narrative review synthesizes and critically evaluates long-term studies examining the effects of TT within the context of aging, obesity, and endogenous sex hormones on CV disease (CVD) risk to support informed clinical decision-making. Observational studies have variably linked low endogenous testosterone with increased CVD risk, while randomized controlled trials (RCTs) demonstrate that TT yields cardiometabolic benefits without increasing short-term CV risk. The TRAVERSE trial, as the first RCT powered to assess CVD events, did not show increased major adverse cardiac events (MACE) incidence; however, its limitations – specifically the maintenance of testosterone at low-normal levels, a high participant discontinuation rate, and short follow-up – warrant a careful interpretation of its results. Furthermore, findings from the TTrials cardiovascular sub-study, which showed an increase in non-calcified plaque, indicate the need for ongoing research into the long-term CV impact of TT. The decision to initiate TT should consider the current evidence gaps, particularly for older men with known CVD. The CV effects of maintaining physiological testosterone levels through exogenous means remain to be fully explored. Until more definitive evidence is available, clinical practice should prioritize individualized care and informed discussions on the potential CV implications of TT.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"84 ","pages":"Pages 14-18"},"PeriodicalIF":9.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of risk profiles of participants in the Women's IschemiA TRial to Reduce events In non-ObstRuctive CAD (WARRIOR) trial, using Coronary Computed Tomography Angiography vs Invasive Coronary Angiography","authors":"Suvasini Lakshmanan ,&nbsp;Janet Wei ,&nbsp;Galen Cook-Wiens ,&nbsp;Carl J. Pepine ,&nbsp;Eileen M. Handberg ,&nbsp;Leslee J. Shaw ,&nbsp;Matthew Budoff ,&nbsp;C. Noel Bairey Merz","doi":"10.1016/j.pcad.2024.03.008","DOIUrl":"10.1016/j.pcad.2024.03.008","url":null,"abstract":"<div><h3>Objective</h3><p>To compare baseline characteristics of participants in the <u>W</u>omen's Ischemi<u>A</u> T<u>R</u>ial to <u>R</u>educe Events <u>I</u>n Non-Obst<u>R</u>uctive CAD (WARRIOR) trial by qualification by Coronary Computed Tomography Angiography (CCTA) or Invasive Coronary Angiography (ICA).</p></div><div><h3>Methods</h3><p>The WARRIOR trial (<span>NCT03417388</span><svg><path></path></svg>) is an ongoing multicenter, prospective, randomized, blinded outcome evaluation of intensive medical therapy vs. usual care in women with suspected Ischemia and No Obstructive Coronary Artery Disease (INOCA) identified by either CCTA or ICA on the outcome of major adverse cardiovascular events (MACE). No obstructive coronary artery disease is defined as &lt;50% luminal stenosis and normal coronary arteries is defined as no evidence of atherosclerosis including calcified and non-calcified plaque. Data presented was extracted on May 27, 2020. No clinical outcomes were assessed.</p></div><div><h3>Results</h3><p>An initial sample cohort of 797 women was included. The majority were younger than 65 years, White participants (73.3%), 159 had diabetes (19.9%), and 676 had angina (84.8%) with the remainder having symptoms of suspected ischemic heart disease. Over 50% of randomized participants had normal coronaries without luminal irregularities by ICA or CCTA. Participants randomized to ICA were more likely to have worse baseline clinical risk profiles with older age, higher burden of cardiac risk factors and poor quality of life with disabling angina.</p></div><div><h3>Conclusions</h3><p>Among this initial sample of women with suspected INOCA randomized in the WARRIOR trial, there is a differential baseline cardiac risk of participants enrolled after CCTA or ICA. However, the majority had no evidence of atherosclerotic plaque or obstructive stenosis, after evaluation by ICA or CCTA. These results suggest that non-invasive evaluation with CCTA is likely to be associated with lower risk of MACE.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"84 ","pages":"Pages 90-93"},"PeriodicalIF":9.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0033062024000537/pdfft?md5=6a499213679ba4b24ca8c705c9dd0be6&pid=1-s2.0-S0033062024000537-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine and plaque: A focus on atherosclerosis imaging","authors":"Jairo Aldana-Bitar ,&nbsp;Ilana S. Golub ,&nbsp;Jeff Moore ,&nbsp;Srikanth Krishnan ,&nbsp;Dhiran Verghese ,&nbsp;Venkat S. Manubolu ,&nbsp;Travis Benzing ,&nbsp;Keshi Ichikawa ,&nbsp;Sajad Hamal ,&nbsp;Sina Kianoush ,&nbsp;Lauren R. Anderson ,&nbsp;Noah R. Ramirez ,&nbsp;Jonathon A. Leipsic ,&nbsp;Ronald P. Karlsberg ,&nbsp;Matthew J. Budoff","doi":"10.1016/j.pcad.2024.02.010","DOIUrl":"10.1016/j.pcad.2024.02.010","url":null,"abstract":"<div><p>Colchicine is an anti-inflammatory medication, classically used to treat a wide spectrum of autoimmune diseases. More recently, colchicine has proven itself a key pharmacotherapy in cardiovascular disease (CVD) management, atherosclerotic plaque modification, and coronary artery disease (CAD) treatment. Colchicine acts on many anti-inflammatory pathways, which translates to cardiovascular event reduction, plaque transformation, and plaque reduction.</p><p>With the FDA's 2023 approval of colchicine for reducing cardiovascular events, a novel clinical pathway opens. This advancement paves the route for CVD management that synergistically merges lipid lowering approaches with inflammation inhibition modalities. This pioneering moment spurs the need for this manuscript's comprehensive review. Hence, this paper synthesizes and surveys colchicine's new role as an atherosclerotic plaque modifier, to provide a framework for physicians in the clinical setting. We aim to improve understanding (and thereby application) of colchicine alongside existing mechanisms for CVD event reduction.</p><p>This paper examines colchicine's anti-inflammatory mechanism, and reviews large cohort studies that evidence colchicine's blossoming role within CAD management. This paper also outlines imaging modalities for atherosclerotic analysis, reviews colchicine's mechanistic effect upon plaque transformation itself, and synthesizes trials which assess colchicine's nuanced effect upon atherosclerotic transformation.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"84 ","pages":"Pages 68-75"},"PeriodicalIF":9.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive medicine and cardiac CT- Their move into mainstream medicine","authors":"Matthew J. Budoff","doi":"10.1016/j.pcad.2024.05.006","DOIUrl":"10.1016/j.pcad.2024.05.006","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"84 ","pages":"Page 1"},"PeriodicalIF":9.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}